WELCOME TO REGEN THERAPEUTICS PLC

The core business activities of ReGen Therapeutics Plc are:

• The global commercialisation of Colostrinin™ as a nutraceutical product
• The development of Colostrinin™ peptides as pharmaceutical drug candidates
• The development of a new use for an existing drug, zolpidem

ReGen Therapeutics Plc was formed in February 1998 to develop Colostrinin™, a proline-rich polypeptide complex derived from mammalian colostrum. Colostrinin™ is promoted as having utility as a support for healthy brain ageing and cognition.  Peptides derived from Colostrinin™ are viewed as having potential in the treatment of neurodegenerative illnesses such as Alzheimer’s disease, Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis.

The Company is now rolling out Colostrinin™ as a nutraceutical product worldwide.  Since 2006, the Company has announced it has signed a number of deals with independent distributors to commercialise Colostrinin™ in North America, Australasia, Cyprus, Greece, Turkey and the Balkans, Poland and the United Kingdom, and it continues to negotiate arrangements for other regions.

In addition to products for human consumption, the Company is also seeking industry partners to continue the development of a veterinary nutraceutical version of Colostrinin™, as a therapy for companion animals.

In parallel to the development of Colostrinin™ as a nutraceutical, ReGen has continued research into the properties of the peptides contained within the Colostrinin™ complex. The peptide programme had presented some interesting compounds for further development to a pre-clinical stage.  The Company’s scientists selected three candidates, two of which may have potential utility in treating Alzheimer’s disease and a further candidate with potential utility in the treatment of obesity.  The first stage of this development is now complete and the findings on all three peptides are being reviewed by two global companies. 

In 2007 ReGen acquired the rights to develop a new use for an existing drug, zolpidem, for the treatment of secondary brain dormancy in human subjects who have suffered significant head trauma, where it has been shown that zolpidem can normalise areas of brain dormancy secondary to a primary lesion in brain damage conditions. The clinical effects of this dormancy reversal have been restoration of consciousness, swallowing, co-ordination and motor function after stroke and traumatic brain injury.  The project is now being offered for licensing out or co-development.

Last updated
4th January 2010